Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
188
-
Total 13F shares, excl. options
-
123M
-
Shares change
-
+299K
-
Total reported value, excl. options
-
$2.23B
-
Value change
-
+$6.55M
-
Put/Call ratio
-
0.56
-
Number of buys
-
81
-
Number of sells
-
-80
-
Price
-
$18.17
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2018
223 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2018.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 188 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 123M shares
of 124M outstanding shares and own 99.16% of the company stock.
Largest 10 shareholders include Third Security, LLC (14.1M shares), Vanguard Group Inc (13.3M shares), BlackRock Inc. (11.9M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (9.23M shares), BB BIOTECH AG (8.25M shares), STATE STREET CORP (4.34M shares), Invesco Ltd. (4.18M shares), JPMORGAN CHASE & CO (3.6M shares), PICTET ASSET MANAGEMENT LTD (3.37M shares), and Thrivent Financial for Lutherans (3.14M shares).
This table shows the top 188 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.